Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation
October 20, 2017
Sophia Antipolis, France and Belfast, Northern Ireland
Nicox SA (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and Re-Vana Therapeutics Ltd, ocular pharmaceutical and drug delivery company, today announced that they have entered into a research collaboration to explore combining Nicox’s next generation of stand-alone nitric oxide (NO)-donors with Re-Vana’s EyeLief™ long-acting photo-crosslinked biodegradable drug delivery platform for the reduction of intraocular pressure (IOP), a key risk factor for the development and progression of glaucoma.
Michael Bergamini, Nicox’s Executive Vice President and Chief Scientific Officer, stated, “Re-Vana’s technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO-donors. EyeLief™ technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP. We look forward to working with Re-Vana on this innovative research endeavor.“
“The Nicox team has built a strong dataset demonstrating the role of nitric oxide in the reduction of IOP,” commented Michael O’Rourke, President & CEO of Re-Vana Therapeutics. “We believe that our biodegradable photo-crosslinked sustained delivery technology, EyeLief™, in combination with Nicox’s novel technology, has the potential to serve as an effective therapeutic approach to lowering IOP to prevent the progression and development of glaucoma.”
The non-exclusive collaboration will focus on the development of the EyeLief™ drug delivery platform for sustained release of certain of Nicox’s next generation of stand-alone NO-donors. EyeLief™ is a novel sustained-release, photo-crosslinked, preformed, biodegradable implant technology intended to release therapeutics over an extended period of time after insertion in the eye.
Under the terms of the agreement, Re-Vana will be responsible for the development and characterization of EyeLief™ implants containing Nicox’s NO-donors, and subsequently for initial in vitro evaluation of the implants’ sustained-release characteristics over a number of months. New jointly-developed intellectual property from the collaboration relating to these sustained-release formulations will be jointly owned. Depending on the outcome of the research collaboration under this agreement, Nicox and Re-Vana may then enter into discussions regarding the further development of other product candidates. Payments by Nicox associated with this agreement are not considered material to Nicox’s financial statements at this time.
Glaucoma is a group of ocular diseases in which the optic nerve is injured, leading to peripheral and, ultimately, central visual loss. Glaucoma can eventually lead to blindness if not treated. Glaucoma is frequently linked to abnormally high intraocular pressure (IOP), due to blockage or malfunction of the eye’s aqueous humor drainage system. Current medications are targeted at reducing IOP to slow the progression of the disease. Numerous eye drops are available to either decrease the amount of fluid produced in the eye or improve its flow out of the eye. A significant portion of patients with open-angle glaucoma require more than one medication to lower their IOP within target levels, highlighting the need for more effective treatments.
About Nicox’s Next Generation of Stand-alone NO-donors
Nicox’s research team has engineered a novel chemistry for a next generation of stand-alone NO-donating molecules with the potential to optimize NO dosing to be used alone or in combination with existing standard-of-care drugs, either as topical eye drops or in sustained intraocular drug-delivery devices. The preclinical results obtained after repeat dosing in rabbit models of glaucoma demonstrate rapid and sustained IOP-lowering compared to vehicle following repeated dosing one hour apart over the course of four hours with no signs of tachyphylaxis or ocular discomfort1. Furthermore, NO-donors result in low tolerance liability as they were found to repeatedly lower IOP on assessed days in these models following twice daily administration over seven days. Similar tolerance liability results were found in non-human primates.
1. Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma, E. Bastia, F. Impagnatiello, E. Ongini, J. Serle, M. Bergamini. Presented at ARVO 2017